Market Withdrawal, Relabeling Cut Cough Med-Linked ER Visits
(HealthDay News) – Voluntary market withdrawal and labeling revision correlated with reductions in the number of emergency department visits for cold and cough medication (CCM) adverse drug events (ADEs) in young children, according to a study published online Nov. 11 in Pediatrics.
Lee M. Hampton, MD, from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues estimated the impact of voluntary market withdrawal and labeling revision of over-the-counter CCMs on emergency department visits for CCM ADEs before and after each intervention. Data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance for 2004–2011 were used.
The researchers observed a decrease in the number of emergency department visits for CCM ADEs among children younger than 2 years, from 4.1% of all ADE visits before market withdrawal to 2.4% afterward. There was also a decrease noted in emergency department visits for CCM ADEs among children aged 2–3 years, from 9.5% of all ADE visits before labeling revision to 6.5% afterward. After market withdrawal and labeling revision, most CCM ADE emergency department visits among children younger than 2 and aged 2–3, respectively, were related to unsupervised ingestion (64.3% and 88.8%, respectively).
"Although progress has been made in reducing ADE emergency department visits from supervised administrations of CCMs, more remains to be done to decrease all types of CCM ADEs among children," the authors write. "Addressing unsupervised ingestions has the greatest potential for further reductions in CCM ADEs."